三阴性乳腺癌组织中BCL11A的表达及新辅助化疗的影响

目的:探讨BCL11A在三阴性乳腺癌(TNBC)中的表达,以及新辅助化疗对其表达的影响。方法:用免疫组化检测BCL11A在43例TNBC癌组织标本(新辅助化疗前后),以及49例管腔型乳腺癌与50例HER-2阳性型乳腺癌癌组织标本中的表达。比较BCL11A在不同类型乳腺癌中的表达差异,分析BCL11A表达与TNBC临床病理因素的关系,以及新辅助化疗对TNBC组织BCL11A表达的影响。结果:TNBC组织中BCL11A的阳性表达率与表达量均明显高于管腔型乳腺癌与HER-2阳性型乳腺癌组织(均P0.05);BCL11A的阳性表达与TNBC原发肿块大小明显有关(P0.05);新辅助化疗后TNBC组织BCL11A的阳性表达率与表达量较新辅助化疗前均明显降低(均P0.05)。结论:BCL11A在TNBC组织中表达升高,且可能是肿瘤增殖的促进因素,新辅助化疗能降低TNBC组织BCL11A的表达。

BCL11A expression in triple-negative breast cancer tissue and its response to neoadjuvant chemotherapy

Objective: To investigate the BCL11A expression in triple-negative breast cancer (TNBC) tissue, and the impact of neoadjuvant chemotherapy on its expression. Methods: The BCL11A expressions in 43 specimens of TNBC (before and after neoadjuvant chemotherapy), as well as in 49 specimens of luminal type breast cancer and 50 cases of HER-2 positive breast cancer were determined by immunochemical staining. The relations of BCL11A expression with the clinicopathologic factors of TNBC and the influence of neoadjuvant chemotherapy on BCL11A expression in TNBC were analyzed. Results: The positive expression rate and expression level of BCL11A in TNBC tissue were significantly higher than those in luminal type breast cancer tissue or HER-2 positive breast cancer tissue (all P<0.05); the positive BCL11A expression was significantly associated with the size of the primary tumor of TNBC (P<0.05); both positive expression rate and expression level of BCL11A in TNBC tissue after neoadjuvant chemotherapy were significantly reduced compared with TNBC tissue before neoadjuvant chemotherapy (both P<0.05). Conclusion: BCL11A expression is increased in TNBC tissue, which may probably be a proliferation promoting factor, and neoadjuvant chemotherapy can reduce BCL11A expression in TNBC tissue.